| Dr Alicia Calderon Bhambra, DO | |
|
101 The City Dr S, Orange, CA 92868-3201 | |
| (626) 676-6499 | |
| Not Available |
| Full Name | Dr Alicia Calderon Bhambra |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 17 Years |
| Location | 101 The City Dr S, Orange, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386943645 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 20A10848 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Yosemite Pathology Medical Group Inc | 3072415751 | 46 |
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Promising new research by US scientists has shown the potential for brain stem cells to be used to cure diabetes. The work by Stanford University researchers, though not yet ready to be tested on human patients, has shown promising results in animals.
OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche today announced that a Phase III study of Tarceva™ (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva™ living longer than those in the placebo arm of the study.
The world's largest randomized controlled trial of the use of acupuncture in emergency departments has found the treatment is a safe and effective alternative to pain-relieving drugs for some patients.
Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease, according to researchers at The University of Texas M. D. Anderson Cancer Center.
› Verified 9 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Promising new research by US scientists has shown the potential for brain stem cells to be used to cure diabetes. The work by Stanford University researchers, though not yet ready to be tested on human patients, has shown promising results in animals.
OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche today announced that a Phase III study of Tarceva™ (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva™ living longer than those in the placebo arm of the study.
The world's largest randomized controlled trial of the use of acupuncture in emergency departments has found the treatment is a safe and effective alternative to pain-relieving drugs for some patients.
Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease, according to researchers at The University of Texas M. D. Anderson Cancer Center.
› Verified 9 days ago
| Entity Name | University Of California Sfgh Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154396208 PECOS PAC ID: 5496668410 Enrollment ID: O20031113000632 |
News Archive
Promising new research by US scientists has shown the potential for brain stem cells to be used to cure diabetes. The work by Stanford University researchers, though not yet ready to be tested on human patients, has shown promising results in animals.
OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche today announced that a Phase III study of Tarceva™ (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva™ living longer than those in the placebo arm of the study.
The world's largest randomized controlled trial of the use of acupuncture in emergency departments has found the treatment is a safe and effective alternative to pain-relieving drugs for some patients.
Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease, according to researchers at The University of Texas M. D. Anderson Cancer Center.
› Verified 9 days ago
| Entity Name | Yosemite Pathology Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598760985 PECOS PAC ID: 3072415751 Enrollment ID: O20040217000597 |
News Archive
Promising new research by US scientists has shown the potential for brain stem cells to be used to cure diabetes. The work by Stanford University researchers, though not yet ready to be tested on human patients, has shown promising results in animals.
OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche today announced that a Phase III study of Tarceva™ (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva™ living longer than those in the placebo arm of the study.
The world's largest randomized controlled trial of the use of acupuncture in emergency departments has found the treatment is a safe and effective alternative to pain-relieving drugs for some patients.
Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease, according to researchers at The University of Texas M. D. Anderson Cancer Center.
› Verified 9 days ago
| Entity Name | Precision Pathology Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295797355 PECOS PAC ID: 7719974153 Enrollment ID: O20040428000676 |
News Archive
Promising new research by US scientists has shown the potential for brain stem cells to be used to cure diabetes. The work by Stanford University researchers, though not yet ready to be tested on human patients, has shown promising results in animals.
OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche today announced that a Phase III study of Tarceva™ (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva™ living longer than those in the placebo arm of the study.
The world's largest randomized controlled trial of the use of acupuncture in emergency departments has found the treatment is a safe and effective alternative to pain-relieving drugs for some patients.
Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease, according to researchers at The University of Texas M. D. Anderson Cancer Center.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alicia Calderon Bhambra, DO 4301 Northstar Way, Modesto, CA 95356-9262 Ph: (209) 577-1200 | Dr Alicia Calderon Bhambra, DO 101 The City Dr S, Orange, CA 92868-3201 Ph: (626) 676-6499 |
News Archive
Promising new research by US scientists has shown the potential for brain stem cells to be used to cure diabetes. The work by Stanford University researchers, though not yet ready to be tested on human patients, has shown promising results in animals.
OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche today announced that a Phase III study of Tarceva™ (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva™ living longer than those in the placebo arm of the study.
The world's largest randomized controlled trial of the use of acupuncture in emergency departments has found the treatment is a safe and effective alternative to pain-relieving drugs for some patients.
Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease, according to researchers at The University of Texas M. D. Anderson Cancer Center.
› Verified 9 days ago
Qun Wang, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S Bldg 1, Orange, CA 92868 Phone: 714-456-6141 | |
Richard S Newman, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: Uci Medical Center, 101 The City Drive South, Orange, CA 92868 Phone: 714-456-2986 | |
Arjun Tudi Reddy, MD, MBA Pathology Medicare: Not Enrolled in Medicare Practice Location: 101 The City Dr S Rm 3003, Orange, CA 92868 Phone: 714-506-0737 | |
Xiaohui S Zhao, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: Uci Medical Center, 101 The City Drive South, Orange, CA 92868 Phone: 714-456-2986 | |
Dr. Sindhuja Sivanandham, MBBS Pathology Medicare: Medicare Enrolled Practice Location: 101 The City Dr S Rm 3003, Orange, CA 92868 Phone: 714-456-8888 | |
Navneet Narula, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: Uci Medical Center, 101 The City Drive South, Orange, CA 92868 Phone: 714-456-2986 | |
Dr. Cassiana Euzebio Bittencourt, MD Pathology Medicare: Medicare Enrolled Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-5439 |